Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs Wegovy Mounjaro GLP-1 Medications Obesity Treatments Semaglutide Clinical Trials Orforglipron Obesity Treatment GLP-1 Receptor Agonists

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Lower-cost semaglutide generics are winning buyers in a price-sensitive market.

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Government Offers GP Bonuses to Speed NHS Mounjaro Prescribing

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Private GLP-1 Weight-Loss Use in UK Skews to Middle-Class Women, Analysis Shows

NHS Starts Targeted Mounjaro Prescribing as Norfolk–Waveney ICB Estimates Over 11,000 Eligible

Serena Williams’ Super Bowl Ro Ad Promotes GLP-1 Weight Loss, Draws Backlash

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

Jefferies Model Links GLP-1 Weight Loss Use to $580 Million in Annual Airline Fuel Savings

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

New Review Finds Rapid Weight Return After Stopping GLP-1 Weight-Loss Drugs

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill